35results about How to "Reduce the frequency of injections" patented technology

Methods and compositions are disclosed to engineer plastids comprising heterologous genes encoding immuno-activating domains fused to an extracellular domain (ECD) of a receptor or surface glycoprotein, a growth factor or an enzyme and produced within a subcellular organelle, such as a chloroplast. The immuno-activating domains may include those regions of a protein capable of modulating the interaction between immune effector cells via proteins containing stereoselective binding domains and specific ligands, such as the Fc regions of antibodies. The present disclosure also demonstrates the utility of plants, including green algae, for the production of complex multi-domain fusion proteins as soluble bioactive therapeutic agents.

The invention discloses a long-acting recombinant human follicle-stimulating hormone-Fc fusion protein (hFSH-Fc) and a preparation method thereof. The hFSH-Fc is a dimerization fusion protein. An amino acid sequence of the hFSH-Fc comprises an hFSHbeta subunit, CTP (carboxy-terminal peptide), an hFSHalpha subunit, a flexible peptide linker and a human IgG (immunoglobulin G) Fc variant from the N terminal to the C terminal in sequence. The hFSH-Fc has longer half-life in vivo and smaller side effects than existing hFSH. The invention also relates to an application of a recombinant hFSH-Fc composition to preparation of drugs for treating and/or preventing infertility.

The invention provides a fusion protein used for detecting and treating human I-type diabetes mellitus and human II-type diabetes mellitus and obesity as well as a preparation and an application of the fusion protein. The fusion protein contains a human FGF21 or a mutant thereof and a human IgG2-Fc (hinge region -CH2-CH3) or a human IgG2-Fc mutant ( T250Q/M428L and T307Q/N434A), can improve the living condition of the obesity patients, reduce the blood sugar level of diabetics, effectively reduce aggregation and degradation of the FGF21 protein, and meanwhile prolong in vivo half-life period of the FGF21, and especially through the fusion of the FGF21 and the mutant and the IgG-Fc (T250Q/M428L and T307Q/N434A) mutant, the affinity with FcRn is enhanced, and in vivo half-life period of the FGF21 is further prolonged.

The present invention discloses a modified exendin or pharmaceutically acceptable salts thereof, wherein the modified exendin comprises an amino acid sequence having at least 90% sequence identity to SEQ ID No. 17 and the amino acid sequence has a higher stability than the non-modified exendin of SEQ ID No. 4. These compounds are useful in treating type 2 diabetes as GLP-1 receptor agonists.

The invention discloses hyperglycosylated human growth hormone fusion protein. The human growth hormone fusion protein sequentially contains a human growth hormone (hGH), a flexible peptide joint (L), human chorionic gonadotropin beta-carboxyl terminal rigid peptide (CTP) and a human immunoglobulin Fc fragment from the N terminal to the C terminal. The invention further discloses a method for efficiently preparing the fusion protein. Compared with a recombinant hGH, the built fusion protein has more excellent in-vivo drug efficacy, the in-vivo circulation half-life period is prolonged, the administration frequency is greatly decreased, and the bioavailability is improved; meanwhile, the production process is simpler and more efficient.

The invention discloses a recombinant human chorionic gonadotrophin-Fc fusion protein (HCG-Fc for short) and a preparation method thereof. The HCG-Fc protein is a dimerized fusion protein, and the amino acid sequence of the fusion protein sequentially comprises an HCG beta subunit, an HCG alpha subunit, a flexible peptide joint and a human IgG Fc mutant from an N end to a C end. Compared with the existing chorionic gonadotrophin, the fusion protein has longer in-vivo half life, higher bioavailability and lower side effect. The invention also relates to an application of a recombinant HCG-Fc fusion protein composition in preparation of medicaments for treating and/or preventing infertility.

The present invention provides long acting parenteral pharmaceutical compositions comprising a therapeutically effective amount of glatiramer. In particular, the present invention provides a long acting pharmaceutical composition comprising a therapeutically effective amount of glatiramer acetate in depot form suitable for administering at a medically acceptable location in a subject in need thereof. The depot form is suitable for subcutaneous or intramuscular implantation or injection.

The invention relates to stable aqueous solution of a recombinant human serum albumin-interferon alpha fusion protein and belongs to the technical field of biological preparations. The aqueous solution of the recombinant human serum albumin-interferon alpha fusion protein is prepared by dissolving the recombinant human serum albumin-interferon alpha fusion protein and pharmaceutically acceptable stable auxiliary material in pharmaceutically acceptable buffer solution, and is characterized in that the pharmaceutically acceptable stable auxiliary material is arginine at a concentration of 5 to 30 g/L. The aqueous solution of therecombinant human serum albumin-interferon alpha fusion protein can prevent the aggregation, degradation, oxidation, denaturation and the like of the recombinant fusion protein effectively so as to retain bioactivity and is suitable to be used in clinic.

The invention relates to a pH response insulin slow release nanoparticle, and a preparation method and an application thereof, and concretely discloses a triblock copolymer. The triblock copolymer is an A-B-C block copolymer, wherein the A block is biodegradable polyethylene glycol monomethyl ether, and the molecular weight is 4000-6000; the B block is polycaprolactone, and the molecular weight is 8000-15000; and the C block is N,N-diethylaminoethyl polybasic polymethacrylate, and the molecular weight is 8000-12000. The pH response insulin slow release nanoparticle is formed by a nanocapsule formed by self-assembling the triblock polymer and insulin loaded on the nanocapsule. The nanoparticle can accurately deliver drugs according to different pH values, and can simultaneously reach sustained and controlled release effects.

Disclosed is a composition for treating retinopathy comprising thrombin derived peptide as an effective component.

The present disclosure relates to a method for the sustained release of a drug, comprising the steps of: (a) preparing a biocompatible polymer having a hydrophobic group conjugated to the biocompatible polymer; and (b) contacting the biocompatible polymer to the drug for adsorbing the drug to the hydrophobic group of the biocompatible polymer, thereby obtaining a drug delivery carrier for the sustained release of the drug; wherein the drug is a protein, a peptide or a non-hydrophilic chemical drug; wherein when the drug adsorbed to the hydrophobic group of the biocompatible polymer is administered to a mammal, it shows a sustained release profile in the mammal. The drug delivery carrier according to the present disclosure having the hydrophobic group conjugated to the biocompatible polymer may be useful for adsorption of synthetic drugs having very low solubility in water. Further, it may regulate discharge rate of adsorbed drugs by regulating a portion of hydrophobic groups conjugated to the polymeric material. Thus, the present disclosure provides a broad-spectrum platform technology applicable to new hydrophobic synthetic drugs to be developed in the future as well as those that have been developed already but face difficulties due to low bioavailability.

The present invention provides compositions and methods of use thereof for treating or ameliorating multiple sclerosis (MS) by administering a depot formulation comprising 40 mg glatiramer acetate intramuscularly to the MS patient.

The invention discloses a recombined human coagulation factor FVII-Fc fusion protein, a preparation method thereof and applications thereof. The fusion protein successively comprises, from the N end to the C end, human FVII, a flexible peptide joint and an IgG2Fc mutant. The Fc mutant has no lysis property and exhibits very low bad Fc-mediated side effect. The fusion protein has similar or higher bioactivity than the human FVII, and prolonged the serum half time, thus improving pharmacokinetics and efficacy.

The invention relates to a stable recombinant human serum albumin-interferon alpha fusion protein water solution, belonging to the technical field of biological agents. The stable recombinant human serum albumin-interferon alpha fusion protein water solution is prepared by dissolving a recombinant human serum albumin-interferon alpha fusion protein and a pharmaceutically acceptable stability adjuvant in a pharmaceutically acceptable buffer solution. The invention is characterized in that the pharmaceutically acceptable stability adjuvant is arginine, and the concentration is 5-30 g/L. The recombinant human serum albumin-interferon alpha fusion protein water solution provided by the invention can sufficiently prevent the recombinant fusion protein from aggregation, degradation, oxidation, denaturization or the like, thereby keeping the biological activity of the recombinant fusion protein; and the recombinant human serum albumin-interferon alpha fusion protein water solution is suitable for clinical application.